Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia

Transplant Infectious Disease

Volumn 12, Issue 1, 2010, Pages 11-15

  Orlando, G ^a,b   Tariciotti, L ^c   Manzia, T M ^c   Gravante, G ^d   Sorge, R ^c   Manuelli, M ^c   Pisani, F ^e   Di Cocco, P ^e   Scelzo, C ^f   Burke, G M ^a   Soker, S ^a   Baiocchi, L ^c   Lerut, J ^g   Angelico, M ^c   Tisone, G ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d LEICESTER GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Immunosuppression; Liver transplant; Monotherapy; PCP; Pneumocystis jirovecii; Pneumonia; Prophylaxis; Trimethoprim sulfamethoxazole

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; CEFTIZOXIME; COTRIMOXAZOLE; CYCLOSPORIN; ITRACONAZOLE; NYSTATIN; PIPERACILLIN; PREDNISONE; TAZOBACTAM; TEICOPLANIN;

ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DESCRIPTIVE RESEARCH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK REDUCTION;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RISK; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77149162383     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00449.x     Document Type: Article

References (31)

1. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001 286 : 2450 2460.
2. Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation - how effective and for how long? Transplantation 1992 53 : 586 589.
3. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999 28 : 240 246.
4. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001 33 : 1397 1405.
5. Olsen SL, Renlund DG, O'Connell JB, et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation 1993 56 : 359 362.
6. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977 297 : 1419 1426.
7. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987 316 : 1627 1632.
8. Dummer JS. Pneumocystis carinii infections in transplant recipients. Semin Respir Infect 1990 5 : 50 57.
9. Higgins RM, Bloom SL, Hopkin JM, Morris PJ. The risks and benefits of low-dose cotrimoxazole prophylaxis for Pneumocystis pneumonia in renal transplantation. Transplantation 1989 47 : 558 560.
10. Torre-Cisneros J, de la Mata M, Lopez-Cillero P, Sanchez-Guijo P, Mino G, Pera C. Effectiveness of daily low-dose cotrimoxazole prophylaxis for Pneumocystis carinii pneumonia in liver transplantation - an open clinical trial. Transplantation 1996 62 : 1519 1521.
11. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 357 : 2601 2614.
12. Almaslmani M, Derbala MF, Albozom I, Khattab M, Chacko K, Alani A. Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis jiroveci infection in orthotopic liver transplantation. Transpl Infect Dis 2008 10 : 339 342.
13. Trotter JF, Levi M, Steinberg T, Lancaster J. Absence of Pneumocystis jiroveci pneumonia in liver transplantation recipients receiving short-term (3-month) prophylaxis. Transpl Infect Dis 2008 10 : 369 371.
14. Tisone G, Angelico M, Palmieri G, et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999 67 : 1308 1313.
15. Tisone G, Orlando G, Vennarecci G, et al. Spontaneous resolution of severe acute rejection in liver transplantation. Transplant Proc 1999 31 : 3164 3166.
16. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 6 : 262 274.
17. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the innovative therapies in sepsis. Crit Care Med 1992 20 : 864 874.
18. Baiocchi L, Angelico M, De Luca L, et al. Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans. Transpl Int 2006 19 : 389 395.
19. Martínez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118 (8 2845 2857.
20. Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007 7 : 309 319. (Pubitemid 46096324)
21. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006 44 : 702 709.
22. Orlando G, Manzia T, Baiocchi L, Sanchez-Fuego A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression trial in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008 20 : 43 47.
23. Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P. Minimization of steroids in liver transplantation. Transpl Int 2009 22 : 2 19.
24. Orlando G, Soker S, Wood KJ. Operational tolerance after liver transplantation. J Hepatol 2009 50 : 1247 1257.
25. Sanchez-Fueyo A, Strom TB. Immunological tolerance and liver transplantation. J Hepatol 2004 41 : 698 705.
26. Stephenson GR, Moretti EW, El-Moalem H, Clavien PA, Tuttle-Newhall JE. Malnutrition in liver transplant patients: preoperative subjective global assessment is predictive of outcome after liver transplantation. Transplantation 2001 72 : 666 670.
27. Lerut J, Mathys J, Verbaandert C, et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomised, double-blind, placebo-controlled study. Ann Surg 2008 248 : 956 967.
28. Karam V, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003 76 : 1699 1704.
29. WHO. WHO Scientific Working Group on Monitoring and Management of Bacterial Resistance to Antimicrobial Agents. Geneva : WHO, 1994.
30. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 357 : 2601 2614.
31. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008 61 : 26 38.